DCM
TBPH icon

DAFNA Capital Management’s Theravance Biopharma TBPH Stock Holding History

DAFNA Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-732,345
Closed -$10.6M – 87
2021
Q2 		$10.6M Buy
732,345
+691,180
+1,679% +$13M 2.22% 5
2021
Q1 		$840K Buy
+41,165
New +$782K 0.2% 75

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

DAFNA Capital Management's TBPH Position: Q3 2021 in Review

DAFNA Capital Management sold out of Theravance Biopharma (TBPH) in Q3 2021, closing a stake of 732,345 shares — an estimated $10.6M sold.

DAFNA Capital Management first reported a position in TBPH in Q1 2021 and held it in 2 quarters. The position peaked at $10.6M in Q2 2021. 119 funds tracked by Wall St. Rank hold TBPH as of Q3 2021.

  • DAFNA Capital Management reported no remaining Theravance Biopharma position as of Q3 2021 after selling out during the quarter.
  • DAFNA Capital Management sold 732,345 Theravance Biopharma shares in Q3 2021, an estimated $10.6M.
  • DAFNA Capital Management first reported a position in Theravance Biopharma in Q1 2021 and held it in 2 quarters.
  • DAFNA Capital Management's Theravance Biopharma position peaked at $10.6M in Q2 2021.
  • 119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2021.

Based on DAFNA Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.